Boehringer, Click DTx for schizophrenia clears pivotal trial Boehringer Ingelheim and Click Therapeutics have revealed the data behind their pivotal trial of a digital therapeutic for schizophrenia.

#Boehringer #ClickDTx #schizophrenia #mentalhealth #psychiatry #BoehringerIngelheim #ECNP #phase3 #CONVOKEtrial #CT155 #CAINSMAP #interactivepsychosocialintervention #antipsychoticdrugtreatment #prescriptiondigitaltherapeutics #breakthroughdevicestatus #FDA
zurl.co/OXeAl